Welcome to our dedicated page for Prime Medicine SEC filings (Ticker: PRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Prime Medicine, Inc. (Nasdaq: PRME) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a public biotechnology company, Prime Medicine uses forms such as Form 8-K, Form 10-Q, Form 10-K and proxy statements to report material events, financial results, governance matters and other information related to its Prime Editing gene editing platform and pipeline.
Recent Form 8-K filings for Prime Medicine have covered topics such as quarterly financial results and business highlights, preliminary cash and investment balances, underwritten public offerings of common stock, option repricing approvals, changes in executive leadership, and the posting of updated corporate presentations. These filings help investors understand how the company is funding research and development for programs in Wilson’s Disease, Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis and other areas, as well as how it manages equity compensation and corporate governance.
Definitive proxy materials, such as the company’s DEF 14A, describe matters submitted to stockholders, including proposals related to equity plans and special meetings. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide more detailed information on Prime Medicine’s operations, risk factors, research and development expenses, and other aspects of its business as a biotechnology issuer focused on Prime Editing-based therapies.
On Stock Titan, Prime Medicine filings are updated as they are made available through EDGAR. AI-powered tools summarize key points from lengthy documents, helping users quickly identify items such as new financing arrangements, changes in leadership roles, special stockholder meetings, and other material events disclosed in Forms 8-K and related exhibits. Users can also review filings that may include information about stock-based compensation, equity offerings, and other capital structure changes relevant to PRME shares.
Chief Technical Officer Ann L. Lee filed a Form 4 showing a one-time repricing of 361,990 stock options originally granted under Prime Medicine’s 2019 and 2022 equity plans. On 08-01-2025 shareholders approved lowering the exercise price of the affected options from $12.30 and $8.49 to $4.04, the closing share price on the repricing date.
- Each original grant (180,995 options expiring 03-31-2033 and 180,995 options expiring 02-21-2034) was cancelled (coded “D”) and immediately re-granted (coded “A”) at the new strike.
- No change in the total number of options or underlying common shares; ownership remains 361,990 options, direct.
- All other terms, including vesting schedules, remain unchanged.
The filing signals management’s desire to restore the retention and incentive value of underwater options after PRME’s share price decline. While it is cash-neutral and non-dilutive today, repricing can draw shareholder-rights scrutiny because it rewards executives for past price under-performance without imposing new performance hurdles.
Prime Medicine (PRME) Form 4: Director Thomas Cahill reported a one-time repricing of four previously granted stock-option blocks on 08/01/2025. Options carrying exercise prices of $14.83 (39,062 shares) and $7.68 (45,000 shares) were cancelled (Code D) and simultaneously re-granted at $4.04 (Code A) for identical share amounts and original expirations (06/14/2033 and 06/12/2034, respectively). The new price equals PRME’s Nasdaq closing price on the repricing date, as approved by stockholders under the 2019 and 2022 equity plans. All vesting schedules and terms remain unchanged. Following the transactions, Cahill beneficially owns 84,062 options at the reduced strike, all held directly.
No open-market share movement or cash consideration occurred; the filing solely reflects the governance-approved adjustment intended to restore incentive value after a share-price decline.
Reine Allan, who is listed as both Chief Executive Officer and a director of Prime Medicine, reported a one-time repricing of certain outstanding stock options effective August 1, 2025. Stockholders approved reducing the per-share exercise price of the affected options to $4.04 from the prior $6.80, aligning the exercise price with the closing market price on the repricing date. The filing shows 850,000 options were repriced and remain governed by their original terms except for the new exercise price; these awards were issued under the 2019 and/or 2022 stock plans and retain their existing vesting schedules and expiration dates (noted as 01/17/2034). The repriced options become exercisable only as they vest and subject to continued service.